Get the Stockscreener App
8.3952
3.09%
-0.3348
Annovis Bio Inc stock is traded at $8.3952, with a volume of 64,108.
It is down -3.09% in the last 24 hours and up +0.59% over the past month.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
See More
Previous Close:
$8.73
Open:
$8.69
24h Volume:
64,108
Relative Volume:
0.28
Market Cap:
$113.96M
Revenue:
-
Net Income/Loss:
$-56.20M
P/E Ratio:
-2.3516
EPS:
-3.57
Net Cash Flow:
$-39.97M
1W Performance:
-13.23%
1M Performance:
+0.59%
6M Performance:
+63.32%
1Y Performance:
+32.81%
1-Day Range:
$8.37
$8.8121
1-Week Range:
$8.40
$9.78
52-Week Range:
$4.53
$22.49
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio - GlobeNewswire
Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Annovis Bio (NYSE:ANVS) Raised to Buy at Maxim Group - MarketBeat
Annovis Bio to Present Key Alzheimer’s Research at CTAD Conference - MSN
Annovis Bio (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies - Barchart
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 - The Manila Times
Annovis Bio files three drug patents - Pennsylvania Business Report
Annovis Bio: Funding May Be An Issue For Announced Phase 3 Trials (NYSE:ANVS) - Seeking Alpha
Annovis Bio To Continue Alzheimer's Disease Clinical Trials (NYSE:ANVS) - Seeking Alpha
Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug - Yahoo Finance
Annovis Bio shares hold Buy rating from HC Wainwright - Investing.com India
Annovis Bio Stock Surges As Analyst Reiterates ‘Buy’ On Alzheimer’s Drug Progress: Retail Stays Bullish - Barchart
Annovis Bio shares hold Buy rating from HC Wainwright By Investing.com - Investing.com UK
In the Green: Annovis Bio Inc (ANVS) Closes at 7.98, Up/Down 6.26 from Previous Day - The Dwinnex
Annovis Bio (NYSE:ANVS) Given Buy Rating at HC Wainwright - MarketBeat
(ANVS) Investment Analysis and Advice - Stock Traders Daily
Annovis Bio Advances Alzheimer’s Treatment with FDA Approval for Phase 3 Trials - MyChesCo
Annovis Bio (ANVS) Stock Soars After FDA Approval - Stocks Telegraph
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs - The Manila Times
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs - GlobeNewswire
Freedom Village Hosts Successful Third Annual Walk to End Alzheimer’s - MyChesCo
(ANVS) On The My Stocks Page - Stock Traders Daily
Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail
ANVSAnnovis Bio, Inc. Latest Stock News & Market Updates - StockTitan
Brookline Capital Initiates Coverage of Annovis Bio (ANVS) with Buy Recommendation - MSN
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases - ForexTV.com
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for ... - The Bakersfield Californian
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Rating of "Buy" from Analysts - MarketBeat
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Three Patents Covering Combination Therapies for AD, PD - MSN
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations - The Manila Times
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential - GlobeNewswire
19,907 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by XTX Topco Ltd - Defense World
Annovis Bio Files Patents for Innovative Therapies in Neurodegenerative Disease Treatment - MSN
Annovis Bio stock outlook supported by innovative neurodegenerative therapies - Investing.com India
Annovis Bio: Against The Grain In Alzheimer's Disease - Life Science Leader Magazine
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition - cnhinews.com
Annovis Bio (NYSE:ANVS) Rating Reiterated by HC Wainwright - MarketBeat
Annovis Bio files three new patents for combination therapies - TipRanks
Annovis Bio files patents for neurodegenerative treatment combos - Investing.com
Annovis Bio Files Patents for Neurodegenerative Combination Therapies - TipRanks
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra - GlobeNewswire
Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom - Seeking Alpha
Anavex Lf SC (AVXL-Q) QuotePress Release - The Globe and Mail
Longeveron Inc (LGVN-Q) QuotePress Release - The Globe and Mail
(ANVS) Long Term Investment Analysis - Stock Traders Daily
Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia - MyChesCo
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):